Prognostic utility of pre-transplantation [18 F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage chemotherapy.
Charles MesguichAlexandre RochElif HindiéNoël MilpiedLaurence BordenaveGhoufrane TliliKrimo BouabdallahPublished in: British journal of haematology (2019)
We analysed the outcomes of 62 patients with refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) who had pre-transplantation fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after R-DHAC (rituximab, dexamethasone, high-dose cytarabine, carboplatin) salvage chemotherapy, and were evaluated using Deauville criteria and total lesion glycolysis (TLG). A positive pre-transplantation PET/CT with Deauville score of 5 was associated with shorter progression-free survival (PFS) (P = 0·01), while a Deauville score of 4 was not predictive of outcome. Only pre-transplant TLG was significantly associated with both PFS (P = 0·005) and overall survival (P = 0·03). TLG deserves to be further investigated in prospective studies.
Keyphrases
- positron emission tomography
- diffuse large b cell lymphoma
- high dose
- pet ct
- computed tomography
- low dose
- epstein barr virus
- free survival
- stem cell transplantation
- pet imaging
- acute myeloid leukemia
- cell therapy
- magnetic resonance imaging
- phase ii study
- locally advanced
- randomized controlled trial
- type diabetes
- stem cells
- glycemic control
- image quality
- dual energy
- magnetic resonance
- hodgkin lymphoma
- chemotherapy induced
- mass spectrometry
- atomic force microscopy